Stockreport

Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

Disc Medicine, Inc.  (IRON) 
PDF Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study parameters wit [Read more]